The estimated Net Worth of Daryl C Drummond is at least $1.6 Million dollars as of 12 May 2017. Dr Drummond owns over 4,097 units of Merrimack Pharmaceuticals Inc stock worth over $1,601,178 and over the last 8 years he sold MACK stock worth over $0.
Dr has made over 2 trades of the Merrimack Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 4,097 units of MACK stock worth $11,021 on 12 May 2017.
The largest trade he's ever made was exercising 4,097 units of Merrimack Pharmaceuticals Inc stock on 12 May 2017 worth over $11,021. On average, Dr trades about 1,171 units every 0 days since 2017. As of 12 May 2017 he still owns at least 105,828 units of Merrimack Pharmaceuticals Inc stock.
You can see the complete history of Dr Drummond stock trades at the bottom of the page.
Dr. Daryl C. Drummond Ph.D. is the Head of Research at Merrimack Pharmaceuticals Inc.
Dr D is 52, he's been the Head of Research of Merrimack Pharmaceuticals Inc since . There are 7 older and 4 younger executives at Merrimack Pharmaceuticals Inc. The oldest executive at Merrimack Pharmaceuticals Inc is Dr. Anthony J. Sinskey Ph.D., Sc.D., 81, who is the Co-Founder and Scientific Advisor.
Daryl's mailing address filed with the SEC is C/O MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE, MA, 02139.
Over the last 13 years, insiders at Merrimack Pharmaceuticals Inc have traded over $1,152,598 worth of Merrimack Pharmaceuticals Inc stock and bought 3,978,994 units worth $28,464,218 . The most active insiders traders include Eric Western Standard Llcwe..., Robert J. Mulroy und Gary L Crocker. On average, Merrimack Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $459,997. The most recent stock trade was executed by Eric Western Standard Llcwe... on 26 December 2023, trading 49,550 units of MACK stock currently worth $651,583.
merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.
Merrimack Pharmaceuticals Inc executives and other stock owners filed with the SEC include: